Pharma Equity Group Cash Flow Statement

Financials in millions DKK. Fiscal year is January - December.

Millions DKK. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Net Income	-25.38	-40.61	-24.35	-9.44
Depreciation & Amortization	0.31	0.24	0.22	0.54
Stock-Based Compensation	-	-	-	0.22
Provision & Write-off of Bad Debts	8.12	16.19	-	-
Other Operating Activities	-0.46	1.32	-0.29	-0.37
Change in Accounts Receivable	-0.17	1.87	-1.36	0.16
Change in Accounts Payable	-0.23	-1.09	2.02	0.86
Change in Other Net Operating Assets	0.15	-0.77	2.73	-0.26
Operating Cash Flow	-17.66	-22.86	-16.62	-8.3
Capital Expenditures	-	-	-0.07	-
Sale of Property, Plant & Equipment	0.01	-	-	-
Investing Cash Flow	0.01	-	-0.07	-
Short-Term Debt Issued	2.97	13.1	5.25	-
Long-Term Debt Issued	-	11.02	8	-
Total Debt Issued	2.97	24.11	13.25	-
Short-Term Debt Repaid	-1.19	-32.32	-4.33	-
Long-Term Debt Repaid	-4.92	-11.87	-0.2	-0.28
Total Debt Repaid	-6.11	-44.19	-4.53	-0.28
Net Debt Issued (Repaid)	-3.14	-20.07	8.72	-0.28
Issuance of Common Stock	-	51.15	12.19	-
Other Financing Activities	17.06	-8.21	-3.85	-
Financing Cash Flow	13.91	22.86	17.06	-0.28
Miscellaneous Cash Flow Adjustments	-	-	1.04	-
Net Cash Flow	-3.74	0	1.4	-8.57
Free Cash Flow	-17.66	-22.86	-16.7	-8.3
Free Cash Flow Per Share	-0.01	-0.02	-0.01	-0.01
Cash Interest Paid	0.56	4.07	1.43	0.02
Cash Income Tax Paid	-	-2.23	-1.86	-1.48
Levered Free Cash Flow	-10.26	-14.7	-65.07	-
Unlevered Free Cash Flow	-8.66	-11.6	-64.1	-
Change in Working Capital	-0.25	0.01	3.39	0.76

Source: S&P Capital IQ. Standard template. Financial Sources.